Protective effect of A(H5N8) stockpiled vaccine against a virus genetically identical to a human isolate of bovine A(H5N1) influenza virus
This finding highlights the vaccine's potential utility during the early phase of an emerging pandemic threat.
Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants
maternal RSVpreF vaccination was associated with 78% to 81% reduction in RSV-associated hospitalization from birth through 6 months of age, with the highest vaccine effectiveness in earliest age intervals.
Mapping in-cell protein contact sites reveals hijacking of paraspeckles during influenza A virus infection
These findings uncover mechanisms by which Influenza A virus exploits and remodels host compartments during infection.
In the media
News
Reports
Demographic transformation in the EU: challenges and opportunities
European population declining, but living longer than ever
In the media
News
Reports
Guidance for integrated respiratory virus surveillance in Europe
Guidance aims to help countries across Europe detect changes in virus circulation earlier and build a clearer picture of respiratory disease trends to increase timely and effective action.
Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
The findings suggest that the high-dose vaccine may improve health outcomes while reducing healthcare costs in people aged 65 and over in Italy.
High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis
Among adults 65 years and older, does high-dose inactivated influenza vaccine (HD-IIV) provide superior protection against hospitalization and mortality compared with the standard dose?
Influenza Vaccine and Associated Infection and Death in California, 2024 to 2025
Among adults aged 65 years and older with laboratory confirmed influenza, vaccination was associated with 29% lower likelihood of death due to influenza-related causes.
